← Atlas Theme · spans 1 topics

Where no approved therapy exists, historical controls become sufficient evidence.

Facing fatal diseases with zero treatment options, developers and regulators substitute external control arms, historical cohorts, and open-label single-arm data for concurrent placebo trials — even granting full approval on an uncontrolled study.

Topics it spans

Findings citing it

—

Evidence window

The convergence

The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:

Science & Health

FDA Approves Fayuvi — First-Ever Treatment for Sanfilippo Syndrome Type A, and Ultragenyx's Second Gene Therapy Approval in a Month

Facing a uniformly fatal disease with no options, the regulator granted full approval on an uncontrolled single-arm study benchmarked against a historical control cohort.

Science & Health

Skyhawk's Oral SKY-0515 Shows First-of-Its-Kind Clinical Signals in Huntington's Disease: +1.59 cUHDRS vs External Control at 15 Months, >60% mHTT Knockdown

With no approved Huntington's therapy in existence, external natural-history controls are standing in for placebo arms as the evidence base for a drug's signal.

Science & Health

uniQure's AMT-130 at Four Years: 44% Slowing of Huntington's Progression — but the Key Score Loses Statistical Significance, and the Stock Craters

With no disease-modifying option existing, the entire pivotal case rests on 12 patients measured against a historical database whose updates eroded the headline signal.

Science & Health

uniQure Secures FDA Path for Accelerated Approval of AMT-130 in Huntington's Disease

The regulator reversed its demand for a sham-controlled trial and accepted propensity-matched external-control data because Huntington's has no approved disease-modifying option.